{"id":"azd6244-dosing-period-4","safety":{"commonSideEffects":[{"rate":"30%","effect":"Diarrhea"},{"rate":"25%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1614701","moleculeType":"Small molecule","molecularWeight":"457.69"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting MEK1/2, AZD6244 blocks the activation of ERK, leading to reduced proliferation and survival of cancer cells that depend on this pathway.","oneSentence":"AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:57:52.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors with RAS or BRAF mutations"}]},"trialDetails":[{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT01635023","phase":"PHASE1","title":"A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Healthy Volunteers","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD6244"],"phase":"phase_1","status":"active","brandName":"AZD6244 Dosing Period 4","genericName":"AZD6244 Dosing Period 4","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway. Used for Advanced solid tumors with RAS or BRAF mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}